Atlas Trials

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Clinical trial NCT02044120 · COMPLETED

Trial details

NCT number
NCT02044120
Sponsor
Sarcoma Alliance for Research through Collaboration
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Ewing Sarcoma
Start date
2014-05-01
Primary completion
2021-01-01
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.